-
Cabozantinib combined with nivolumab prolongs the overall survival of patients with advanced kidney cancer
Time of Update: 2021-04-14
This article from the NEJM meta-Journal (NEJM Journal Watch) Cabozantinib plus Nivolumab Improves Overall Survival in Advanced Kidney Cancer Cabozantinib joint Carolina Wu Li You monoclonal antibody in patients with advanced kidney cancer prolongs overall survival comment author: Robert Dreicer, MD, MS , MACP, FASCO in patients receiving combination therapy, progression-free survival and overall survival are longer than those receiving TKI sunitinib treatment.
-
Kangfang Bio-PD-1 obtained FDA breakthrough therapy qualification, third-line treatment of metastatic nasopharyngeal carcinoma
Time of Update: 2021-04-14
FDAIn September 2020, Kangfang Bio announced that the registered clinical trial of Paimrizumab for the third-line treatment of metastatic nasopharyngeal carcinoma reached the primary endpoint of objective response rate (ORR) assessed by independent imaging, after previous multi-line treatment Among the patients with nasopharyngeal cancer, they have shown good clinical efficacy and safety, and will communicate with NMPA before applying for new drugs.
-
A must-see for women!
Time of Update: 2021-04-14
Although many women take the recommended dose of tamoxifen (20 mg) for a long time, although it can prevent breast cancer, it also causes a variety of side effects that cannot be ignored.
-
The world's fifth CAR-T therapy was approved by the FDA for marketing, targeting BCMA
Time of Update: 2021-04-14
On March 26, 2021, Abecma (idecabtagene vicleucel; ide-cel), a CAR-T cell therapy product jointly developed by BMS (Bristol-Myers Squibb) and Bluebird (Bluebird Bio) , was officially approved for marketing by the FDA .
-
Progress in the treatment of newly diagnosed diffuse large B-cell lymphoma
Time of Update: 2021-04-14
The results of a phase II clinical trial showed that [11], newly diagnosed patients with limited-stage DLBCL can achieve CMR after only 3 cycles of R-CHOP treatment, using PET/CT assessment.
-
MPN Case Inventory | Analysis of Difficulties in Diagnosis and Treatment of MPN Disease
Time of Update: 2021-04-14
Auxiliary blood test: HGB: 57g/L Biochemistry: LDH: 2486U/L Abdominal color Doppler ultrasound: liver size and shape is normal, spleen color super thick meridian: 110mm, oblique meridian 281mm Gene detection: JAK2V617F mutation positive case diagnosis Post-PV MF (IPSS: 2 points, DIPSS: 3 points, intermediate risk-2) After diagnosis and treatment, thalidomide 50 mg qd, stanozolol 2 mg bid, blood transfusion, diuresis, and infection control after 2020-02.
-
CStone's retransmission of precision treatment drug Taijihua® is approved for marketing, and Chinese patients with gastrointestinal stromal tumors usher in new therapies
Time of Update: 2021-04-14
Approved for the treatment of unresectable or metastatic GIST adult patients with PDGFRA exon 18 mutation is based on an open-label, multi-center phase I/II clinical study aimed at evaluating Taijihua?
-
Up-regulation of histone deacetylase 6 is associated with the malignancy of melanoma and the prognosis of patients
Time of Update: 2021-04-14
In recent years, more and more researchers have devoted themselves to exploring the biological characteristics of melanoma, but there are no clinical biomarkers that can predict the occurrence and development of melanoma.
-
[Science Sub-Journal] Photothermal Therapy|Platelet meritorious service!
Time of Update: 2021-04-14
The biomimetic formulation realizes an efficient tumor photothermal-immune combined therapy on an animal model, which is not only conducive to more removal of tumor cells, but also conducive to inhibiting tumor metastasis and recurrence.
-
The Nobel Prize winner team develops a new anti-cancer "weapon": reprogram cancer cells into cancer stem cells within 24 hours
Time of Update: 2021-04-14
Recently, in a new study published in "Nature Biomedical Engineering" (IF=19), a research team led by Professor Shinya Tanaka from Hokkaido University in Japan has developed an innovative hydrogel that can dissolve 6 Different types of human cancer cell lines are transformed into cancer stem cells.
-
Siddi Medicine obtains the exclusive authorization of the new generation of CD47 antibody drug in Greater China
Time of Update: 2021-04-14
On March 31, 2021, Sidi Medicine, located in the Shanghai International Medical Park of Zhangjiang Science City, announced that it has obtained ImmuneOncia Therapeutics' new generation anti-CD47 monoclonal antibody IMC-002 tumor indication in Greater China (Mainland China, Hong Kong, Macau and Taiwan) The exclusive authorization for the development, production and commercialization of The company plans this year to the State Drug Administration submitted a clinical trial application (IND) Bureau (NMPA).
-
Guo Xiaohuan’s team reveals a new mechanism by which gut microbes promote anti-cancer drug efficacy through metabolites | Cell Press Dialogue Scientist
Time of Update: 2021-04-14
"The research paper reported that butyric acid, a metabolite of intestinal microbes, can increase the efficacy of anti-tumor drugs by enhancing the immune response of CD8+ T cells.
-
Heal her·Newborn | Southern Breast Cancer Diagnosis and Treatment Summit Forum was grandly held, big coffees gathered to explore hot issues in breast cancer treatment
Time of Update: 2021-04-14
Professor Chen Qianjun first pointed out that the 6-year iDFS subgroup analysis results of the APHINITY study showed that compared with the control group, the double-target adjuvant treatment with Trapa increased the 6-year DFS rate of patients with positive lymph nodes by 4.
-
Qingli Xinsheng breaks advanced gastrointestinal stromal tumors——Congratulations on Qingle® (Repetinib tablets) approved in China
Time of Update: 2021-04-14
March 31, 2021-Zai Lab announced that the National Medical Products Administration (NMPA) of China has approved the marketing application of Qingle® (Repetinib tablets) for the treatment of those who have received imatinib Adult patients with advanced gastrointestinal stromal tumor (GIST) with 3 or more kinase inhibitors.
-
More than liver cancer!
Time of Update: 2021-04-14
, this study adds more evidence for the association between non-alcoholic fatty liver disease and a variety of digestive system cancers, lung cancer, and increased risk of breast cancer.
-
Tojo Pharmaceuticals: In-depth layout of the development and commercialization of anti-tumor ADC drugs
Time of Update: 2021-04-14
Antibody-conjugated drugs (ADC) have both the cytotoxicity of small molecules and the targeting properties of monoclonal antibodies.
At present, the fastest ADC drug developed by Toyo Pharmaceutical is TAA013.
-
How can Golly Pharma enter the oncology market?
Time of Update: 2021-04-14
In the 2020 European Medical Oncology Conference (ESMO), a researcher-initiated application of the FASN inhibitor TVB-2640 (Gree code: ASC40) combined with bevacizumab for the treatment of glioblastoma II was announced Phase clinical results showed that the objective response rate (ORR) of the program reached 65%, of which the complete response rate (CR) was 20%, the partial response rate (PR) was 45%; the 6-month PFS rate was 47%, which was significantly better than Historical control (BELOB 16%, P=0.
-
Express | Reduce the risk of disease progression by 45%, Sanofi's CD38 antibody combination therapy is approved by the FDA
Time of Update: 2021-04-14
▎The content team editor of WuXi AppTec today, Sanofi announced that the US FDA has approved its CD38 antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) standard therapies to treat relapse/difficulty Treatment of multiple myeloma (MM) patients.
-
The University of Wisconsin-Madison Weibo Cai Research Group AS: CD38-targeted lymphoma radiological diagnosis and treatment research
Time of Update: 2021-04-14
Abstract: Weibo Cai from the University of Wisconsin, Kang Lei from Peking University First Hospital and their collaborators labelled 89Zr and 177Lu on the CD38-targeting monoclonal antibody darlimumab, which can not only monitor the CD38 expression of living tumors by PET imaging Moreover, one administration after labeling with 177Lu can significantly inhibit the growth of CD38-positive lymphoma, providing an effective candidate for clinical diagnosis and treatment in the future.
-
NEJM: Nivolumab adjuvant treatment program was successfully used in the Phase III clinical study of patients with advanced esophagus or gastroesophageal junction cancer
Time of Update: 2021-04-14
For patients with esophageal cancer or gastroesophageal junction cancer who need neoadjuvant chemoradiation, nivolumab adjuvant therapy is significantly better than placebo in terms of disease-free survival.
